Abstract
The concept of bioavailability of drugs was developed by pharmacists. They introduced it to reflect the fact that the way in which a drug is formulated can determine its absorption and therefore the onset and magnitude of its action. To define a drug formulation’s bioavailability is to define both the rate and the extent of that drug’s entry into the circulation and tissues of the body from the site of administration. In brief, it describes how fast and how fully the drug gets to the tissues. Bioavailability is determined by the drug’s chemical characteristics, by the method of formulation and also by physiological factors acting on the administration route. It can be calculated from blood levels of the drug or from the amounts excreted in the urine. The techniques are described below.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Aldous, S., Thomas, R.: Absorption and metabolism of lanatoside C. II. Fate after oral administration. Clin. Pharmacol. Ther. 21, 647–658 (1977)
Andersson, K.E., Nyberg, L., Dencker, H., Gothlin, J.: Absorption of digoxin in man after oral and intrasigmoid administration studied by portal vein catheterisation. Eur. J. Clin. Pharmacol. 9, 39–47 (1975)
American Pharmaceutical Association. Guidelines for biopharmaceutical studies in man. Washington 1972
Azarnoff, D.L., Huffman, D.H.: Therapeutic implications of bioavailability. Ann. Rev. Pharmacol. Toxicol. 16, 53–66 (1976)
Banes, D.: Drug quality control: problem with digoxin. FDA Drug. Bull. p. 2. (1971)
Bazzano, G., Bazzano, G.S.: Digitalis intoxication: treatment with a new steroid-binding resin. J. Am. Med. Assoc. 220, 828–830 (1972)
Beckett, A.H., Cowan, D.A.: Differences in the dissolution rate of generic digoxin tablets. Pharm. J. 211, 111–112 (1973)
Beerman, B.: On the fate of orally administered 3H-lanatoside C in man. Eur. J. Clin. Pharmacol. 5, 11–18 (1972a)
Beerman, B.: The gastrointestinal uptake of methyldigoxin 12a-H3 in man. Eur. J. Clin. Pharmacol. 5, 28–33 (1972b)
Beerman, B., Hellstrom, K., Rosen, A.: Fate of orally administered 3H-digitoxin in man with special reference to the absorption. Circulation 43, 852–861 (1971)
Beerman, B., Hellstrom, K., Rosen, A.: The gastrointestinal absorption of digoxin in seven patients with gastric or small intestinal reconstructions. Acta Med. Scand. 193, 293–297 (1973)
Bever, R.J.V., Duchateau, A.M.J.A., Pluym, B.F.M., Merkus, F.W.H.M.: The effect of col-estipol on digitoxin plasma levels. Arzneim. Forsch. (Drug Res.) 26, 1891–1893 (1976)
Beveridge, T., Kalberger, E., Neusch, E., Schmidt, R.: Bioavailability studies with Digoxin-Sandoz and Lanoxin. Eur. J. Clin. Pharmacol. 8,371–376 (1975)
Binnion, P.F.: Absorption of different commercial preparations of digoxin in human subjects, and the influence of antacid, antidiarrhoeal and ion exchange resins. In: Digitalis. Storstein (ed.), pp. 216–224. Oslo: Gyldendal Norsk Forlag 1973
Binnion, P.: A comparison of the bioavailability of digoxin in capsule, tablet and solution taken orally with intravenous digoxin. J. Clin. Pharmacol. 16, 461–467 (1976)
Bochner, F., Huffman, D.H., Shen, D.D., Azarnoff, D.L.: Bioavailability of digoxin-hydro-quinone complex: a new oral digoxin formulation. J. Pharm. Sci. 1753–1758 (1976)
Bodem, G., Wirth, K., Gernand, E., Dengler, H.J.: Pharmacokinetics and metabolism of acetyldigoxin in man. Arch. Int. Pharmacodyn. 208, 102–116 (1974)
Boerner, D., Olcay, A., Schaumann, W., Weiss, W.: Absorption of ß-methyldigoxin determined after a single dose and under steady state conditions. Eur. J. Clin. Pharmacol. 9, 307–314 (1976)
Brachtel, R., Gilfrich, H.J.: Die intestinale Resorption von Digoxin bei Patienten mit progressiver Sklerodermie. Klin. Wochenschr. 55, 439–444 (1977)
Brodie, B.B., Heller, W.M. (ed.).: Bioavailability of drugs. Basel: Karger 1972
Brown, D.D., Juhl, R.P.: Decreased bioavailability of digoxin due to antacids and kaolin-pectin. N. Engl. J. Med. 295, 1034–1037 (1976)
Brown, D.D., Juhl, R.P., Warner, S.L.: Decreased bioavailability of digoxin due to hypocholesterolemic interventions. Circulation 58, 164–172 (1978)
Butler, V.P.: Assays of digitalis in the blood. Prog. Cardiovasc. Dis. 14, 571–600 (1972)
Caldwell, J.H., Greenberger, N.J.: Interruption of enterohepatic circulation of digitoxin by cholestyramine: Protection against lethal intoxication. J. Clin. Invest. 50, 2626–2637 (1971)
Caldwell, J.H., Bush, C.A., Greenberger, N.J.: Interruption of the enterohepatic circulation of digitoxin by cholestyramine. 11. Effect on metabolic disposition of tritium-labelled digitoxin and cardiac systolic time intervals in man. J. Clin. Invest. 50, 2638–2644 (1971)
Danon, A., Horowitz, J., Ben-Zvi, Z., Kaplanski, J., Glick, S.: An outbreak of digoxin toxicity. Clin. Pharmacol. Ther. 21, 643–646 (1977)
Doherty, J.E., Perkins, W.H., Mitchell, G.K.: Tritiated digoxin studies in human subjects. Arch. Intern. Med. 108, 531–539 (1961)
Doherty, J.E., Perkins, W.H.: Studies with tritiated digoxin in human subjects after intravenous administration. Am. Heart J. 63, 528–536 (1962)
Federal Register. 39 2471 (1974)
FDA Drug Bulletin:Digitoxin reformulation - dosage change. 6, 39–40 (1976)
Flasch, H.: Die biologische Verfügbarkeit von ß-Acetyldigoxin und Digoxin. Klin. Wochenschr. 53,873–877 (1975)
Flasch, V.H., Asmussen, B., Heinz, N.: Erhöhte Bioverfügbarkeit von Digoxin aus Kiselsaure-Matrix-Zubereitungen. Arzneim. Forsch. 28, 326–330 (1978)
Fleckenstein, L., Kroening, B., Weintraub, M.: Assessment of the biologic availability of digoxin in man. Clin. Pharmacol. Ther. 16, 435–443 (1974)
Florence, A.T., Salole, E.G., Stehlake, J.B.: The effect of particle size reduction on digoxin crystal properties. J. Pharm. Pharmacol. 26, 479–480 (1974)
Fraser, E.J., Leach, R.H., Poston, J.W.: Dissolution studies with single tablets of digoxin BP. Postgrad. Med. J. 50, (Suppl. 6) 43–47 (1974)
Gault, M.H., Charles, J.D., Sugden, D.L., Kepkay, D.C.: Hydrolysis of digoxin by acid. J. Pharm. Pharmacol. 29, 27–32 (1977)
Gold, H., Cattell, McK., Greiner, T., Hanlon, L.W., Kwit, N.T., Modell, W., Cotlove, E., Benton, J., Otto, H.L.: Clinical pharmacology of digoxin. J. Pharmacol. Exp. Ther. 109, 45–57 (1953)
Greeff, K., Hafner, D., Storbach, H., Wirth, K.E.: Vergleich der biologischen Verfügbarkeit und renalen Elimination von Digitoxin und Digoxin. Herz Kreisl. 11, 221–224 (1979)
Greeff, V.K., Hafner, D., Strobach, H., Wirth, K.E.: Vergleich der Bioverfügbarkeit bzw. enteralen Resorption des Digoxin, ß-Acetyl Digoxins und ß-Methyldigoxins. Arzneim. Forsch. (Drug Res.) 27, (11) 2358–2364 (1977)
Greenblatt, D.J., Duhme, D.W., Koch-Weser, J., Smith, T.W.: Evaluation of digoxin bio-availability in single dose studies. N. Engl. J. Med. 289, 651–654 (1973)
Greenblatt, D.J., Duhme, D.W., Koch-Weser, J., Smith, T.W.: Intravenous digoxin as a bioavailability standard: slow infusion and rapid injection. Clin. Pharmacol. Ther. 15, 510–513 (1974a)
Greenblatt, D.J., Duhme, D.W., Koch-Weser, J., Smith, T.W.: Comparison of one - and six-day urinary digoxin excretion in single dose bioavailability studies. Clin. Pharmacol. Ther. 16, 813–816 (1974b)
Greenblatt, D.J., Duhme, D.W., Koch-Weser, J., Smith, T.W.: Equivalent bioavailability from digoxin elixir and rapid-dissolution tablets. J. Amer. Med. Assoc. 229, 1774–1776 (1974c)
Greenblatt, D.J., Duhme, D.W., Koch-Weser, J., Smith, T.W.: Bioavailability of digoxin tablets and elixir in the fasting and post-prandial states. Clin. Pharmacol. Ther. 16, 444–448 (1974d)
Greenblatt, D.J., Koch-Weser, J.: Clinical pharmacokinetics. N. Engl. J. Med. 293, 702–705, 964–970 (1975)
Greenblatt, D.J., Smith, T.W., Koch-Weser, J.: Bioavailability of drugs: the digoxin dilemma. Clin. Pharmacokinet. 1, 36–51 (1976)
Harter, J.G., Skelly, J.P., Steers, A.W.: Digoxin - the regulatory viewpoint. Circulation 49, 395–398 (1974)
Harter, J.G.: Comments from the Food and Drug Administration. Am. J. Med. 58, 477–478 (1975)
Hall, W.H., Doherty, J.E.: Tritiated digoxin XXII. Absorption and excretion in malabsorption syndromes. Am. J. Med. 56, 437–442 (1974)
Hall, W.H., Shappell, S.D., Doherty, J.E.: Effect of cholestyramine on digoxin absorption and excretion in man. Am. J. Cardiol. 39, 213–216 (1977)
Hartel, G., Manninen, V., Reissell, P.: Treatment of digoxin intoxication. Lancet 1973 11, 158
Heizer, W.D., Smith, T.W., Goldfinger, S.E.: Absorption of digoxin in patients with malabsorption syndromes. N. Engl. J. Med. 285, 257–259 (1971)
Hinderling, P.H., Garret, E.R., Wester, R.C.: Pharmacokinetics of ß-methyldigoxin in healthy humans. 11. Oral Studies and bioavailability. J. Pharm. Sci. 66, 314–325 (1977)
Huffman, D.H., Azarnoff, D.L.: Absorption of orally given digoxin preparations. J. Amer. Med. Assoc. 222,957–960 (1972)
Huffman, D.H., Manion, C.V., Azarnoff, D.L.: Absorption of digoxin from different oral preparations in normal subjects during steady state. Clin. Pharmacol. Ther. 16, 310–317 (1974)
Huffman, D.H., Manion, C.V., Azarnoff, D.L.: Intersubject variation in absorption of digoxin in normal subjects. J. Pharm. Sci. 64, 433–437 (1975)
Iisalo, E., Ruikka, I.: Serum levels and renal excretion of digoxin in the elderly: a compar- ison between three different preparations. Acta Med. Scand. 196, 59–63 (1974)
Johnson, B.F., Greer, H., McCrerie, J., Bye, C., Fowle, A.: Rate of dissolution of digoxin tablets as a predictor of absorption. Lancet 1973 a1,1473–1475
Johnson, B.F., Fowle, A.S.E., Lader, S., Fox, J., Munro-Faure, A.D.: Biological availability of digoxin from Lanoxin produced in the United Kingdom. Br. Med. J. 1973 bIV, 323–326
Johnson, B.F., Lader, S.: Bioavailability of digoxin from rapidly dissolving preparations. Br. J. Clin. Pharmacol. 1, 329–333 (1974)
Johnson, B.F., Bye, C.: Maximal intestinal absorption of digoxin, and its relation to steady state plasma concentration. Br. Heart J. 37, 203–208 (1975)
Johnson, B.F., Bye, C., Jones, G., Sabey, G.A.: A completely absorbed oral preparation of digoxin. Clin. Pharmacol. Ther. 19, 746–751 (1976a)
Johnson, B.F., Bye, C.E., Jones, G.E., Sabey, G.A.: The pharmacokinetics of beta-methyl digoxin compared with digoxin tablets and capsules. Eur. J. Clin. Pharmacol. 10, 231–236 (1976b)
Johnson, B.F., Smith, G., French, J.: The comparability of dosage regimens of Lanoxin tablets and Lanoxicaps. Br. J. Clin. Pharmacol. 4,209–211 (1977)
Johnson, B.F., O’Grady, J., Bye, C.: The influence of digoxin particle size on the absorption of digoxin and the effect of propantheline and metoclopramide. Br. J. Clin. Pharmacol. 5, 465–467 (1978a)
Johnson, B.F., O’Grady, J., Sabey, G.A., Bye, C.: Effect of a standard breakfast on digoxin absorption in normal subjects. Clin. Pharmacol. Ther. 23,315–319 (1978b)
Jounela, A.J., Pentikainen, P.J., Sothman, A.: Effect of particle size on the bioavailability of digoxin. Eur. J. Clin. Pharmacol. 8, 365–370 (1975)
Juhl, R.P., Summers, R.W., Guillory, J.K., Blaug, S.M., Cheng, F.H., Brown, D.D.: Effect of suphasalazine on digoxin bioavailability. Clin. Pharmacol. Ther. 20,387–394 (1976)
Jusko, W.J., Conti, D.R., Molson, A., Kuritzky, P., Giller, J., Schultz, R.: Digoxin absorption from tablets and exilir: the effect of radiation-induced malabsorption. J. Amer. Med. Assoc. 230, 1554–1555 (1974)
Karjalainen, J., Ojala, K., Reissell, P.: Non-equivalent digoxin tablets. Ann. Clin. Res. 6, 132–136 (1974)
Keller, F., Rietbrock, N.: Bioavailability of digoxin: some pitfalls and problems. Int. J. Clin. Pharmacol. 15, 549–556 (1977)
Khalil, S.A.H.: The uptake of digoxin and digitoxin by some antacids. J. Pharm. Pharmacol. 26,961–967 (1974)
Klink, P.R., Poust, R.I., Colaizzi, J.L., McDonald, R.H.: Bioavailability and dissolution properties of two commercial digoxin tablets. J. Pharm. Sci. 63, 1231–1234 (1974)
Klotz, U., Antonin, K.H., Bieck, P.R.: Bioavailability of ß acetyldigoxin after single and repeated doses of tablets and solution. Eur. J. Clin. Pharmacol. 10, 417–424 (1976)
Koch-Weser, J.: Drug therapy: bioavailability of drugs. N. Engl. J. Med. 291, 233–237 and 503–506 (1974)
Kolibash, A.J., Kramer, W.G., Reuning, R.H., Caldwell, J.H.: Marked decline in serum digoxin concentrations during an episode of severe diarrhea. Am. Heart J. 94, 806–807 (1977)
Konig, E., Ohly, A.: Quantitative Eigenschaften eines neuen Herzglykosids. Med. Klin. 65, 296–299 (1970)
Kramer, W.G., Reuning, R.H.: Use of area under curve to estimate absolute bioavailability of digoxin. J. Pharm. Sci. 67, 141–142 (1978)
Kramer, W.G., Kolibash, A.J., Bathala, M.S., Visconti, J.A., Lewis, R.P., Reuning, R.H.: Digoxin bioavailability: evaluation of a genetic tablet and proposed FDA guidelines. J. Pharm. Sci. 66, 1720–1722 (1977)
Lahiri, K., Ertel, N.: Mechanism of diphenylhydantoin induced decrease in serum digoxin levels. Clin. Res. 22, 321A (1974)
Lancet: The bioavailability of digoxin. 2, 311 (1972)
Larbig, D., Scheler, F., Schmidt, H.J., Betzien, G., Kaufmann, B.: Untersuchungen zur en-teralen Resorption von ß-Methyldigoxin. Klin. Wochenschr. 49, 604–607 (1971)
Levy, G., Gibaldi, M.: Bioavailability of drugs; focus on digoxin. Circulation 44, 391–394 (1974)
Levy, G., Nelson, E.: United States Pharmacopoeia and National Formulary Standards, F.D.A. regulations and the quality of drugs. Nr. State J. Med. 61, 4003–4008 (1961)
Levy, G.: Pharmacokinetic control and clinical interpretation of steady state blood levels of drugs. Clin. Pharmacol. Ther. 16, 130–134 (1974)
Lindenbaum, J.: Bioavailability of digoxin tablets. Pharmacol. Rev. 25, 229–237 (1973)
Lindenbaum, J.: Bioavailability from different lots of digoxin tablets from the same manufacturer. Pharmacol. Ther. 17, 296–301 (1975)
Lindenbaum, J.: Greater bioavailability of digoxin solution in capsules: studies in the postprandial state. Clin. Pharmacol. Ther. 21, 278–282 (1977)
Lindenbaum, J., Mellow, M.H., Blackstone, M.O., Butler, V.P.: Variation in biologic avail-ability of digoxin from four preparations. N. Engl. J. Med. 285, 1344–1347 (1971)
Lindenbaum, J., Preibisz, J.J., Butler, V.P., Saha, J.R.: Variation in digoxin bioavailability: a continuing problem. J. Chronic. Dis. 26, 749–754 (1973a)
Lindenbaum, J., Butler, V.P., Murphy, J.E., Cresswell, R.M.: Correlation of digoxin-tablet dissolution rate with biological activity. Lancet 1973b I,1215–1217
Lindenbaum, J., Maulitz, R.M., Butler, V.P.: Inhibition of digoxin absorption by neomycin. Gastroenterology 71, 399–404 (1976)
Lloyd, B.L., Greenblatt, D.J., Allen, M.D., Harmatz, J.S., Smith, T.W.: Pharmacokinetics and bioavailability of digoxin capsules, solution, and tablets after single and multiple doses. Am. J. Cardiol. 42, 129–136 (1978)
Loo, J.C.K., Rowe, M., McGilveray, I.J.: Effect of an antacid on absorption of digoxin in dogs. J. Pharm. Sci. 64, 1727–1728 (1975)
Mallis, G.I., Schmidt, D.H., Lindenbaum, J.: Superior bioavailability of digoxin solution in capsules. Clin. Pharmacol. Ther. 18, 761–768 (1975)
Manninen, V., Melin, J., Hartel, G.: Serum digoxin concentrations during treatment with different preparations. Lancet 1971 II, 934–935
Manninen, V., Korhonen, A.: Inequal digoxin tablets. Lancet 1973 11, 1268
Manninen, V., Apajalahti, A., Melin, J., Karesoja, M.: Altered absorption of digoxin in patients given propantheline and metoclopramide. Lancet 1973a 7, 398–400
Manninen, V., Apajalahti, A., Simonen, H., Reissell, P.: The effect of propantheline and metoclopramide on absorption of digoxin. Lancet 1973b I, 1118–1119
Manninen, V., Reissell, P., Ojala, K.: Maximal bioavailability of digoxin from tablets and oral solution in steady state. Acta Med. Scand. 199, 487–489 (1976a)
Manninen, V., Reissell, P., Paukkala, E.: Transient arrhythmias after single daily maintenance doses of digoxin. Clin. Pharmacol. Ther. 20, 266–268 (1976b)
Marcus, F.I., Dickerson, J., Pippin, S., Stafford, M., Bressler, R.: Digoxin bioavailability: formulations and rates of infusion. Clin. Pharmacol. Ther. 20, 253–259 (1976)
Marcus, F.I., Quinn, E.J., Horton, H., Jacobs, S., Pippin, S., Stafford, M.S., Zukoski, C.: The effect of jejuno-ileal bypass on the pharmacokinetics of digoxin in man. Circulation 55, 537–541 (1977)
Nyberg, L.: Bioavailability of digoxin in man after oral absorption of preparations with different dissolution rate. Acta Pharmacol. Toxicol. 40, (Suppl. III) 1–48 (1977)
Nyberg, L., Andersson, K.E., Fagerstrom, P.O.: Bioavailability of digoxin from tablets: IV. urinary excretion of digoxin during multiple dose treatment. Acta Pharm. Suec. 14, 119–136 (1977)
Notari, R.E.: Biopharmaceutics and pharmacokinetics: an introduction. 2nd ed. New York: Marcel Dekker 1975
Ochs, H., Bodem, G., Schafer, P.K., Kodrat, G., Dengler, H.J.: Absorption of digoxin from the distal parts of the intestine in man. Eur. J. Clin. Pharmacol. 9, 95–97 (1975)
O’Grady, J., Johnson, B.F., Bye, C., Sabey, G.A.: Influence of soft gelatin on digoxin ab-sorption. Br. J. Clin. Pharmacol. 5, 461–463 (1978)
Oser, B.L., Melnick, D., Hochberg, M.: Physiological availability of the vitamins. Study of methods for determining availability in pharmaceutical products. Ind. Eng. Chem. Anal. Ed. 17, 401–411 (1945)
Oudtshoorn, M.C.B., van.: Bioavailability of digoxin. Lancet 197211, 1153 Pharmaceutical Journal: Digoxin licences to be reviewed. Pharm. J. 211, 20 (1973)
Preibisz, J.J., Butler, V.P., Lindenbaum, J.: Digoxin tablet bioavailability: single dose and steady state assessment. Ann. Intern. Med. 81,469–474 (1974)
Reddy, R.K., Khalil, S.A., Gouda, M.W.: Dissolution characteristics and oral absorption of digitoxin and digoxin coprecipitates. J. Pharm. Sci. 65, 1753–1758 (1976)
Redfors, A., Bertler, A., Nilsen, R., Wettre, S.: Changing a population from one digoxin preparation to another. In: Digitalis. Storstein, O. (ed.), pp. 390–395. Oslo: Gyldendal Norsk Forlag 1973
Reissell, P., Manninen, V., Ojala, K., Karjalainen, J.: Non-equivalence of digoxin tablets. Ann. Clin. Res. 6, (Supp1.11) 4–8 (1974)
Reissell, P., Ojala, K., Manninen, V., Sothman, A.: Correlation of digoxin tablet dissolution rate with biological availability. Br. J. Clin. Pharmacol. 4, 235–236 (1977)
Rietbrock, N., Abshagen, U.: Stoffwechsel und Pharmacokinetik der Lanataglykoside beim Menschen. Dtsch. Med. Wochenschr. 98, 117–122 (1973)
Rietbrock, N., Abshagen, U., Bergmann, K., Rennekamp, H.: Disposition of ß-methyldigoxin in man. Eur. J. Clin. Pharmacol.. 9, 105–114 (1975)
Rietbrock, N., Guggenmos, J., Kuhlmann, J., Hess, U.: Bioavailability and pharmacokinetics of ß-methyldigoxin after multiple oral and intravenous doses. Eur. J. Clin. Pharmacol. 9, 373–379 (1976)
Rietbrock, N., Kuhlmann, J.: Pharmakokinetische und klinische Aspekte der Glycosidtherapie bei Herzinsuffizienz. Med. Klin. 72, 435–449 (1977)
Rodgers, E., Dobbs, S.M., Kenyan, W.I., Poston, J.W.: Evaluation of digoxin capsules in outpatients. Brit. Med. J. 1977111, 234–235
Ruiz-Torres, A., Burmeister, H.: Stoffwechsel und Kinetik von ß-Acetyldigoxin. Klin. Wochenschr. 50, 191–195 (1972)
Sanchez, N., Sheiner, L.B., Halkin, H., Melmon, K.L.: Pharmacokinetics of digoxin: interpreting bioavailability. Br. Med. J. 1973 1V, 132–134
Schaumann, W.: Personal communication quoted by Hinderling et al., 1977
Shaw, T.R.D.: Non-equivalence of digoxin tablets in the U.K. and its clinical implications. Postgrad. Med. J. 50, (Suppl. 6) 24–29 (1974)
Shaw, T.R.D., Howard, M.R., Hamer, J.: Variation in the biological availability of digoxin. Lancet 1971 11, 303–307
Shaw, T.R.D., Raymond, K., Howard, M.R., Hamer, J.: Therapeutic nonequivalence of digoxin tablets in the United Kingdom: correlation with tablet dissolution rate. Br. Med. J. 1973 IV, 763–766
Shaw, T.R.D., Carless, J.E.: The effect of particle size on the absorption of digoxin. Eur. J. Clin. Pharmacol. 7, 269–273 (1974)
Shaw, T.R.D., Howard, M.R., Hamer, J.: Recent changes in the biological availability of digoxin: effect of an alteration in `Lanoxin’ tablets. Br. Heart J. 36, 85–89 (1974a)
Shaw, T.R.D., Raymond, K., Greenwood, H.: The biological availability of very rapidly dissolving digoxin tablets. Postgrad. Med. J. 50, (Suppl. 6) 37–40 (1974b)
Sorby, D.L., Tozer, T.N.: On the evaluation of biologic availability of digoxin from tablets. Drug Intell. Clin. Pharm. 7,78–83 (1973)
Smith, T.W.: New approaches to the management of digitalis intoxication. In: Digitalis. Storstein, O. (ed.), pp. 312–323. Oslo: Gyldendal Norsk Forlag 1973
Steiness, E., Svendsen, O., Rasmussen, F.: Plasma digoxin after parenteral administration: Local reaction after intramuscular injection. Clin. Pharmacol. Ther. 16,430–434 (1974)
Stoll, R.G., Christensen, M.S., Sakmar, E., Blair, D., Wagner, J.G.: Determination of bio-availability of digitoxin using the radioimmunoassay procedure. J. Pharm. Sci. 62, 1615–1620 (1973)
Stoll, R.G., Wagner, J.G.: Intravenous digoxin as a bioavailability standard. Clin. Pharmacol. Ther. 17, 117–118 (1975)
Storstein, L.: Studies on digitalis. II. The influence of impaired renal function on the renal excretion of digitoxin and its cardioactive metabolites. Clin. Pharmacol. Ther. 16, 25–34 (1974)
Storz, H.: Die quantitative Wirksamkeit des Herzglykosids B-Methyldigoxin. Med. Welt 21, 2066–2070 (1970)
Thompson, W.G.: Relationship of in vitro binding of digoxin to its intestinal absorption in rats. Can. J. Pharmacol. 51, 832–834 (1973)
Turner, J., Dobbs, S.M., Nicholson, P.W., McGill, A.P.J., Rodgers, E.M.: Influence of diet on digoxin dose requirements. Br. J. Clin. Pharmacol. 4, 489–491 (1977)
Vöhringer, H.F., Kuhlman, J., Rietbrock, N.: Der Einfluß von Antacid auf die Plasma-Konzentration von Digoxin beim Menschen. Dtsch. Med. Wochenschr. 101, 106–108 (1976)
Vöhringer, V.H.F., Wogenstein, H.-M., Rietbrock, N.: Die biologische Verfügbarkeit von Digitoxin. Fortschr. Med. 95, 2323–2331 (1977)
Vöhringer, V. H.-F., Leopold, G., Rietbrock, N.: Die biologische Verfügbarkeit von Digitoxin. Fortschr. Med. 96, 71 (1978)
Wagner, J.G.: Biopharmaceutics and relevant pharmacokinetics. Hamilton: Drug Intelligence Publications 1971
Wagner, J.: Fundamentals of Clinical Pharmacokinetics. Hamilton: Drug Intelligence Publications 1975
Wagner, J.G., Christensen, M., Sakmar, E., Blair, D., Yates, J.D., Willis, P.W., Sedman, A.J., Stoll, R.G.: Equivalence lack in digoxin plasma levels. J. Amer. Med. Assoc. 224, 199–204 (1973)
Wagner, J.G., Ayres, J.W.: Bioavailability assessment: Methods to estimate total area (AUC 0-oc) and total amount excreted (Aeoo) and importance of blood and urine sampling scheme with application to digoxin. J. Pharmacokin. Biopharm. 5, 533–557 (1977)
Wayne, E.J.: Clinical observations on two pure glucosides of digitalis, digoxin and digitalinium verum. Clin. Sci. 1, 63–76 (1933)
Weissler, A.M., Snyder, J.R., Schoenfeld, C.D., Cohen, S.: Assay of digitalis glycosides in man. Am. J. Cardiol. 17, 768–780 (1966)
White, R.J., Chamberlain, D.A., Howard, M., Smith, T.W.: Plasma concentrations of digoxin after oral administration in the fasting and postprandial state. Br. Med. J. 1971 1,380–381
Wirth, K., Bodem, G., Dengler H.J.: In: Aktuelle Digitalis Problems. Schroeder, R., Greeff, K. (eds.), pp. 51–61. München: Urban und Schwarzenberg 1972
Wood, J.H., Blavnagri, V.P., Proctor, J.D., Evans, E.F., Martin, M.F., Kingan, K.L.: Bio-availability of commercial digitoxin preparations. J. Clin. Pharmacol. 15, 568 (1975)
Ylitalo, P., Wilen, G., Lundell, S.: Bioavailability of digoxin tablets in relation to their dissolution in vitro. J. Pharm. Sci. 64, 1264–1266 (1975)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Shaw, T.R.D. (1981). Bioavailability of Cardiac Glycosides. In: Greeff, K. (eds) Cardiac Glycosides. Handbook of Experimental Pharmacology, vol 56 / 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-68166-0_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-68166-0_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-68168-4
Online ISBN: 978-3-642-68166-0
eBook Packages: Springer Book Archive